Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Stirring the pot!!! Lol

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Apr 24, 2023 7:22am

64 Views

Post# 35409927

RE:RE:Stirring the pot!!! Lol

Yes Yes Yes. "Need to be clear now on strategies since the pipeline is a negative on the value at this point --prove to the market you have a lot of ways you are planning to get value and how you'll get it done. Simple and necessary."

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023